Tyra Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Tyra Biosciences, Inc. on May 31, 2023. The filing details the results of shareholder votes regarding director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes or operational updates are disclosed in this filing. The document serves to disclose the outcome of the annual shareholder meeting.
Guidance, Outlook, and Voting Results
Management commentary and financial guidance are not included in this filing. The following matters were voted upon:
- Director Elections: Three Class II directors were elected for a three-year term expiring at the 2026 Annual Meeting.
- Isan Chen, M.D.: 37,336,370 For; 541,765 Withheld.
- Gilla Kaplan, Ph.D.: 37,581,968 For; 296,167 Withheld.
- Robert More: 37,571,418 For; 306,717 Withheld.
- Auditor Ratification: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified.
- Votes For: 40,984,756
- Votes Against: 625
- Abstentions: 1,819
Investor Verification Checklist
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Confirm the term expiration dates for the newly elected Class II directors (2026).
- Review the full proxy statement for detailed biographies of the elected directors and the rationale for the auditor selection.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.